Faculty profile

Nayyer Iqbal

Back to faculty

ProfessorDepartment of MedicineUniversity of Saskatchewan

Signals and details

Research

Read how they describe their research on their University of Saskatchewan profile.

Latest papers

Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.
Breast cancer research and treatment · 2026
Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.
Breast cancer research and treatment · 2026
Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.
Clinical Cancer Research · 2025

All 19 publications

19 publications.

Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.

Ahmed S, Mannala S, Mondal P, Mahmood W, Chalchal HI, Dwernychuk L, Iqbal N, Salim M, Khan MI, Ahmed O, Manna M, Leverick DG, Chandrasekhar A, Bashir A, Haider K, Leis A, Kontulainen S, Sami A

Breast cancer research and treatment2026

DOI: 10.1007/s10549-026-07999-1 PMID: 42360361

Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.

Doyle C, Lohmann AE, Iqbal N, Henning JW, Kulkarni S, Califaretti N, Hilton J, Ferrario C, Bouganim N, Mates M, Guillemette S, Leite R, Caron MA, Thireau F, Machado A, Chia S

Breast cancer research and treatment2026Open Access

DOI: 10.1007/s10549-026-07934-4 PMID: 41854885

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.

Winquist E, Hotte SJ, Chi K, Sridhar S, Ellard S, Ong M, Iqbal N, Salim M, Emmenegger U, Gingerich JR

Clinical Cancer Research202511 citations

DOI: 10.1158/1078-0432.ccr-24-1612

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.

Doyle C, Lohmann AE, Iqbal N, Henning JW, Kulkarni S, Califaretti N, Hilton J, Ferrario C, Bouganim N, Mates M, Guillemette S, Leite R, Caron MA, Thireau F, Machado A, Chia S

Breast cancer research and treatment20253 citationsOpen Access

DOI: 10.1007/s10549-024-07580-8 PMID: 39847203

Outcomes of Rural Men with Breast Cancer: A Multicenter Population Based Retrospective Cohort Study.

Fisher LAB, Ahmed O, Chalchal HI, Deobald R, El-Gayed A, Graham P, Groot G, Haider K, Iqbal N, Johnson K, Le D, Mahmood S, Manna M, Meiers P, Pauls M, Salim M, Sami A, Wright P, Younis M, Ahmed S

Cancers20232 citationsOpen Access

DOI: 10.3390/cancers15071995 PMID: 37046656

Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

Lalani AKA, Heng DYC, Basappa NS, Wood L, Iqbal N, McLeod D, Soulières D, Kollmannsberger C

Therapeutic Advances in Medical Oncology202238 citationsOpen Access

DOI: 10.1177/17588359221108685

Patient and Physician Satisfaction with Telemedicine in Cancer Care in Saskatchewan: A Cross-Sectional Study.

Gondal H, Abbas T, Choquette H, Le D, Chalchal HI, Iqbal N, Ahmed S

Current oncology (Toronto, Ont.)202222 citationsOpen Access

DOI: 10.3390/curroncol29060309 PMID: 35735418

Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).

Mueller V, Wardley A, Paplomata E, Hamilton E, Zelnak A, Fehrenbacher L, Jakobsen E, Curtit E, Boyle F, Harder Brix E, Brenner A, Crouzet L, Ferrario C, Muñoz-Mateu M, Arkenau HT, Iqbal N, Aithal S, Block M, Cold S, Cancel M, Hahn O, Poosarla T, Stringer-Reasor E, Colleoni M, Cameron D, Curigliano G, Siadak M, DeBusk K, Ramos J, Feng W, Gelmon K

European journal of cancer (Oxford, England : 1990)2021

DOI: 10.1016/j.ejca.2021.05.025 PMID: 34214937

Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer

Herberts C, Murtha AJ, Fu S, Wang G, Schönlau E, Xue H, Lin D, Gleave A, Yip S, Angeles A

European Urology202088 citations

DOI: 10.1016/j.eururo.2020.04.058

Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic

Lalani A-KA, Chi KN, Heng DYC, Kollmannsberger CK, Sridhar SS, Blais N, Canil C, Czaykowski P, Hotte SJ, Iqbal N

Journal of the Canadian Urological Association202015 citationsOpen Access

DOI: 10.5489/cuaj.6595 PMID: W3014370738

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Nayyer Iqbal

Research

Latest papers

Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.

Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.

Outcomes of Rural Men with Breast Cancer: A Multicenter Population Based Retrospective Cohort Study.

Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

Patient and Physician Satisfaction with Telemedicine in Cancer Care in Saskatchewan: A Cross-Sectional Study.

Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).

Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer

Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic

Frequent collaborators

Shahid Ahmed

Osama Ahmed

Punam Pahwa

Kamal Haider

Sebastien Hotte

Aly-Khan Lalani

Kim Chi

Alina Lalani

Adnan Zaidi

Muhammad Salim

Haji Chalchal

Eric Winquist

Jan-Willem Henning

Anne Leis

Mita Manna

Amer Sami

Kate Johnson

Srikala Sridhar

Christina Canil

Nadia Califaretti

Alexander Wyatt

Oksana Prokopchuk-Gauk

Vinita Sundaram

Waleed Sabry

Nayyer Iqbal

Research

Latest papers

Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy&#x2009;&#xb1;&#x2009;targeted therapy in HR&#x2009;+&#x2009;HER2-negative advanced breast cancer.

Outcomes of Rural Men with Breast Cancer: A Multicenter Population Based Retrospective Cohort Study.

Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

Patient and Physician Satisfaction with Telemedicine in Cancer Care in Saskatchewan: A Cross-Sectional Study.

Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB&#xa0;trial).

Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer

Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic

Frequent collaborators

Shahid Ahmed

Osama Ahmed

Punam Pahwa

Kamal Haider

Sebastien Hotte

Aly-Khan Lalani

Kim Chi

Alina Lalani

Adnan Zaidi

Muhammad Salim

Haji Chalchal

Eric Winquist

Jan-Willem Henning

Anne Leis

Mita Manna

Amer Sami

Kate Johnson

Srikala Sridhar

Christina Canil

Nadia Califaretti

Alexander Wyatt

Oksana Prokopchuk-Gauk

Vinita Sundaram

Waleed Sabry

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.

Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).